Putin's vaccine meets opposition from frontline workers in Russia | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Tuesday
July 01, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
TUESDAY, JULY 01, 2025
Putin's vaccine meets opposition from frontline workers in Russia

Coronavirus chronicle

TBS Report
06 September, 2020, 04:05 pm
Last modified: 06 September, 2020, 04:16 pm

Related News

  • Syria receives first shipment of Russian shots - report
  • Young Pakistanis rush to purchase Russian vaccine as private sales open
  • Africa proves rocky terrain for Russian and Chinese vaccines
  • EU says no talks under way to buy Russia's Covid-19 vaccine
  • EU regulator says Russia yet to submit Covid-19 vaccine application

Putin's vaccine meets opposition from frontline workers in Russia

Developed by the Moscow-based Gamaleya Institute, the Sputnik-V vaccine was named after the surprise 1957 launch of the world's first satellite by the Soviet Union

TBS Report
06 September, 2020, 04:05 pm
Last modified: 06 September, 2020, 04:16 pm
FILE PHOTO: A handout photo shows an employee demonstrating vials with "Gam-Covid-Vac" vaccine against the coronavirus disease (Covid-19), developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), during its production at Binnopharm pharmaceutical company in Zelenograd near Moscow, Russia August 7, 2020. Picture taken August 7, 2020. The Russian Direct Investment Fund (RDIF)/Andrey Rudakov/Handout via REUTERS
FILE PHOTO: A handout photo shows an employee demonstrating vials with "Gam-Covid-Vac" vaccine against the coronavirus disease (Covid-19), developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), during its production at Binnopharm pharmaceutical company in Zelenograd near Moscow, Russia August 7, 2020. Picture taken August 7, 2020. The Russian Direct Investment Fund (RDIF)/Andrey Rudakov/Handout via REUTERS

Russian authorities have singled out teachers - as well as doctors - as key workers who will get access to the Sputnik-V vaccine first, even before crucial phase 3 human trials have finished.

However, that has not gone down well with some sections of the frontline workers who don't buy Russian President Vladimir Putin's claims of the efficacy of the vaccine and are reluctant to be used as human guinea pigs, reports the CNN.

On September 1, Russian classrooms reopened for the first time since March amid the Covid-19 pandemic - the same day the country surpassed 1 million coronavirus cases. Teachers were meant to be among the first to benefit from Russia's new coronavirus vaccine, especially given the close contact with hundreds of children that they are exposed to on a daily basis. 

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Developed by the Moscow-based Gamaleya Institute, the Sputnik-V vaccine was named after the surprise 1957 launch of the world's first satellite by the Soviet Union. Russia's claim of victory at being the first to approve a coronavirus vaccine in a worldwide pandemic was initially met with widespread concern and unanswered questions over its safety and effectiveness, and not just from outside the country.

A Russian teachers' union, "Uchitel," started an online petition calling on members to reject the vaccine outright on safety grounds, and expressing concern that vaccination - currently voluntary - should not be made mandatory unless clinical trials are complete.

Employees walk on May 20 in a passage at the headquarters of Russia's biotech company BIOCAD, which has been working on a vaccine against the coronavirus.

Reality can differ from promises

Yuri Varlamov, a teacher in Moscow and a member of the union, said he doesn't want to take the vaccine because he doesn't believe it is safe right now.

"Before the end of trials, they cannot make it mandatory. But I know that in some schools and state bodies, people are talking about mandatory status of this vaccine by the end of this year," Varlamov said.

Marina Balouyeva, co-chairman of the "Uchitel" union, said a petition against compulsory vaccination for teachers was more of a precaution.

Balouyeva said she is wary of Sputnik-V for several reasons. "Firstly, it is generally known that the quality of domestic vaccines is worse than that of foreign ones," she said.

"Secondly, the vaccine was created at railway speed, which already raises concerns. It was created in haste."

Despite promises from authorities that taking the vaccine will be voluntary, she said she fears things could go differently in reality, as often happens in Russian state institutions.

Balouyeva said no complaints have yet been made to her union from teachers saying they are being forced to be vaccinated. However, previous experience indicates there have been such problems with other vaccines, she says.

For example, officially, the seasonal flu shot is not mandatory for Russian educational workers -- it is voluntary. But according to Balouyeva some schools require it from their employees without fail.

Whether there will be sanctions on those unwilling to be vaccinated with Sputnik-V, depends on the headteacher. Most schools have a so-called "incentive bonus" - a fund of money that the administration can distribute as they see fit. Some teachers could be deprived of this payment if they don't get the vaccine.

Balouyeva is all too familiar with the consequences that follow if you go against the school administration.

Having successfully worked for 15 years as an English teacher at a correctional school for children with cerebral palsy in St. Petersburg, Balouyeva says she was fired last year for an "unexplained absence" for not working during a school holiday.

It happened shortly after she was publicly vocal about teachers' salaries being lower than figures published in official documents.

"Teachers are a very disenfranchised category, just like doctors," the former teacher said, adding that the temptation to test the vaccine on them is immense. "It is both cheap and practical -- why not do it, from the point of view of the authorities?"

Political pressure

Critics such as Anastasia Vasilyeva, a Russian doctor turned prominent campaigner and ally of Russian opposition leader Alexey Navalny, says the country's push for a vaccine comes amid political pressure from the Kremlin, which is keen to portray Russia as a global scientific force. Navalny is currently being treated in a Berlin hospital after a suspected poisoning attempt in Siberia last month.

"I think it's to show Russia is a big strong country, that Putin is a big strong president," Vasilyeva said.

Her colleague, a surgeon at a hospital in northeast Moscow, shared his concerns about the vaccine, strictly on the condition of anonymity, due to fear of facing repercussions at work, if he came out publicly against the vaccine. When offered the vaccine in early August, he started consulting with experts.

"I am not a vaccine specialist," he admits, "So, I called the doctors who deal with vaccinations, I called immunologists. They said, 'don't do it, by no means, the vaccine is raw.'"

It was a friendly offer, he says, no pressure, no obligations. But no matter how hard the deputy chief physician tried to persuade the surgeon that the vaccine is "perfectly normal, good, amazing," the doctor still was reluctant to try it on himself.

"Explain to me: how could it be that such powerful European and international organizations could not do it, but a relatively small Gamaleya Institute could? I cannot understand it," the surgeon said.

He didn't know when the vaccine would be delivered to his hospital but said very few of his colleagues would have the courage to refuse it.

"Totalitarianism remains [in Russia]. The two most helpless sectors are education and health care. Everything is done forcefully here. Last year I had a flu shot, everyone was told they needed to be vaccinated. And everyone did it, because if you don't, there will be penalties."

But it isn't just doctors and teachers who voiced concerns Russia may have cut essential corners in development.

Polls suggest around half of Russian citizens have doubts about the vaccine, the Moscow Mayor Sergey Sobyanin said on Friday during a video conference with Putin. He added, however, that two months ago, the figure was almost 90 percent.

Sobyanin, who revealed he had been vaccinated with Sputnik-V, was speaking just moments after Russia published its peer-reviewed data from phase 1 and phase 2 clinical trials in The Lancet medical journal, which suggest the Russian vaccine has a good safety profile and produced no serious adverse side effects.

Scientists not involved in the study said while the results are a positive sign, only larger, Phase 3 trials can confirm whether the vaccine actually prevents illness with Covid-19.

The Russian defense minister was also shown getting the shot. It seems Russia's messaging about the vaccine has gone into full overdrive following the publication of its scientific data. It remains to be seen if the tide of public opinion and front-line workers will change over time too.

Top News

Russian Covid-19 Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Chief Adviser Muhammad Yunus and US Secretary of State Marco Rubio. Photos: Collected
    Rubio calls Yunus, discusses economic ties as US tariff negotiation goes on
  • Representational image. File photo: TBS
    Ships depart, cargo operation in full swing as Ctg port starts clearing containers
  • NBR Office in Dhaka. File Photo: Collected
    NBR officers should captain revenue authority, businesses tell finance adviser

MOST VIEWED

  • Return to work or face stern action, govt warns protesters as NBR jobs declared 'essential services'
    Return to work or face stern action, govt warns protesters as NBR jobs declared 'essential services'
  • Representational image. Photo: UNB
    After 58 yrs, Ctg getting two new govt schools
  • Remittance inflow hits record $30b in FY25
    Remittance inflow hits record $30b in FY25
  • Officials of the NBR, under the banner of the NBR Unity Council, continued their protest on Sunday since 9am. Photo: Syed Zakir Hossain/TBS
    NBR staff call off protest as govt goes tough
  • Record $30b remittance lifts reserves to $26b
    Record $30b remittance lifts reserves to $26b
  • A Chevron gas station sign is seen in Del Mar, California, April 25, 2013. Chevron will report earnings on April 26. REUTERS/Mike Blake
    Chevron to resume Jalalabad gas project after Petrobangla clears $237m dues

Related News

  • Syria receives first shipment of Russian shots - report
  • Young Pakistanis rush to purchase Russian vaccine as private sales open
  • Africa proves rocky terrain for Russian and Chinese vaccines
  • EU says no talks under way to buy Russia's Covid-19 vaccine
  • EU regulator says Russia yet to submit Covid-19 vaccine application

Features

Illustration: TBS

Ulan Daspara: Remnants of a fishing village in Dhaka

3h | Panorama
Photo: Collected

Innovative storage accessories you’ll love

1d | Brands
Two competitors in this segment — one a flashy newcomer, the other a hybrid veteran — are going head-to-head: the GAC GS3 Emzoom and the Toyota CH-R. PHOTOS: Nafirul Haq (GAC Emzoom) and Akif Hamid (Toyota CH-R)

GAC Emzoom vs Toyota CH-R: The battle of tech vs trust

1d | Wheels
Women farmers, deeply reliant on access to natural resources for both farming and domestic survival, are among the most affected, caught between ecological collapse and inadequate structural support. Photo: Shaharin Amin Shupty

Hope in the hills: How women farmers in Bandarban are weathering the climate crisis

1d | Panorama

More Videos from TBS

Committee led by DC-UNOs to set up polling stations cancelled

Committee led by DC-UNOs to set up polling stations cancelled

26m | TBS Today
What is the reason behind Russia's refusal to go to war against Israel?

What is the reason behind Russia's refusal to go to war against Israel?

56m | Others
BNP Blamed by Parties as Reforms Lag

BNP Blamed by Parties as Reforms Lag

1h | TBS Today
What are the problems with foreign investment in the renewable energy sector in the country?

What are the problems with foreign investment in the renewable energy sector in the country?

1h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net